Divi's Laboratories

Divi's Laboratories EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Divi's Laboratories (DIVISLAB.NS) as of Oct 23, 2026 is 15.18 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 11.84 % — a change of 28.24% (higher).

EBIT/Assets

15.18 %

YoY

28.24%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Divi's Laboratories is 2025 15.18 % . Operating Income to Assets Ratio (EBIT/Assets) of Divi's Laboratories was 2024 11.84 % . It decreases by 28.24% higher compared to the previous year.

The Divi's Laboratories EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
16.59 INR
Jan 1, 2019
21.22 INR
Jan 1, 2020
19.22 INR
Jan 1, 2021
24.27 INR
Jan 1, 2022
26.71 INR
Jan 1, 2023
14.03 INR
Jan 1, 2024
11.84 INR
Jan 1, 2025
15.18 INR
The Divi's Laboratories EBIT/Assets history
YEAREBIT/AssetsYoY
15.18 %+28.24%
11.84 %-15.64%
14.03 %-47.47%
26.71 %+10.06%
24.27 %+26.29%
19.22 %-9.43%
21.22 %+27.93%
16.59 %-25.06%
22.13 %-16.78%
26.59 %+13.13%
23.51 %-6.05%
25.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Divi's Laboratories Stock analysis

What does Divi's Laboratories do? Divi's Laboratories Ltd. is a pharmaceutical company based in Hyderabad, India. It was founded in 1990 and has become one of the leading manufacturers of active ingredients and formulations for the pharmaceutical industry in recent years. The company was founded by Dr. Murali Divi, who built the company on principles of quality, technology, and innovation. Divi's Laboratories now employs approximately 13,000 employees and operates production facilities in India and the USA. The company operates in various sectors, including generics, custom synthesis, research and development, and nutraceuticals. Its products are used worldwide and are approved in over 95 countries. Divi's Laboratories follows a vertically integrated supply chain model, producing high-quality active ingredients and developing its own formulations for the pharmaceutical industry. The company always relies on innovative technologies and continuous improvement of product quality. Its product range includes a wide range of active ingredients for various therapeutic areas, such as antibiotics, antidepressants, antihypertensives, antidiabetics, static lipid-lowering agents, and antipsychotics. Divi's Laboratories has state-of-the-art production facilities, strict quality controls, and advanced analytical facilities for all pharmaceutical ingredients. In addition to its active ingredients, the company is also known for its custom synthesis services, which involve the production of customer-specific active ingredients for the pharmaceutical industry. Divi's Laboratories offers a tailored service that meets the specific requirements of customers, ranging from the development of new active ingredients and formulations to the production of small or medium quantities of active ingredients. In the area of research and development, Divi's Laboratories works closely with academic institutions and other pharmaceutical companies to leverage the latest scientific knowledge and develop innovative products. The company invests a significant sum in research and development annually. In addition to active ingredients and custom synthesis services, Divi's Laboratories also offers a range of nutraceuticals. These products, such as vitamins, minerals, and other dietary supplements, are used to support a healthy lifestyle. In summary, Divi's Laboratories is an India-based pharmaceutical company specializing in the manufacture of active ingredients and formulations for the pharmaceutical industry. The company operates to the highest quality standards and relies on innovative technologies and sustainable product development. The wide product range and custom synthesis services offer customers a tailored solution for their needs. Divi's Laboratories is a leading provider of active ingredients and has made a name for itself in the pharmaceutical and nutraceutical industry due to its high quality and productivity. Divi's Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Divi's Laboratories stock

Operating Income to Assets Ratio (EBIT/Assets) of Divi's Laboratories is 15.18 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Divi's Laboratories changed from 11.84 % to 15.18 %, representing a 28.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Divi's Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Divi's Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Divi's Laboratories

All Key Metrics — Divi's Laboratories